RCKT Rocket Pharmaceuticals
- 12.570
- +0.540+4.49%
- 12.560
- -0.010-0.08%
Rocket Pharmaceuticals News
Major firms rating丨Wedbush: Initiated coverage on Rocket Pharmaceuticals with an "Outperform" rating.
Wedbush initiates coverage of Rocket Pharmaceuticals with an "Outperform" rating and a Target Price of $32. Ongoing pipeline development and internal capacity are expected to support the company's long-term growth potential. (Gelonghui)
Sector Update: Health Care Stocks Softer Late Afternoon
Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says
Wedbush Starts Rocket Pharmaceuticals With Outperform Into 'Inflection Year'
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $32
Promising Pipeline and Strategic Developments Propel Rocket Pharmaceuticals to 'Buy' Rating
Express News | Rocket Pharmaceuticals Inc : Wedbush Initiates Coverage With Outperform Rating; Price Target $32
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Rocket Pharmaceuticals Price Target Announced at $29.00/Share by Jefferies
Rocket Pharmaceuticals Analyst Ratings
Jefferies Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $29
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $40
Leerink Partners Adjusts Rocket Pharmaceuticals Price Target to $40 From $44, Maintains Outperform Rating
Rocket Pharmaceuticals Shares Are Trading Lower After the Company Announced a $165 Million Upsized Public Offering of 13.2 Million Shares at $12.50 per Share.
Rocket Pharmaceuticals Intends To Offer And Sell $150M Of Shares Of Its Common Stock In Public Offering
Express News | Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
Rocket Pharmaceuticals on Track for Lowest Close Since September 2022 -- Data Talk
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $55
No Data